Apyx Medical Co. (NASDAQ:APYX) Short Interest Update

Apyx Medical Co. (NASDAQ:APYX) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 120,000 shares, a decrease of 14.6% from the November 15th total of 140,500 shares. Based on an average trading volume of 51,300 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.4% of the shares of the stock are sold short.

Institutional Investors Weigh In On Apyx Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royce & Associates LP increased its position in shares of Apyx Medical by 3.4% in the third quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock valued at $3,202,000 after acquiring an additional 85,267 shares during the period. Private Advisor Group LLC increased its holdings in Apyx Medical by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock valued at $400,000 after purchasing an additional 12,180 shares during the period. RPg Family Wealth Advisory LLC bought a new position in Apyx Medical during the 2nd quarter valued at approximately $101,000. Rathbones Group PLC lifted its holdings in Apyx Medical by 148.0% in the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after buying an additional 150,000 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in Apyx Medical by 2.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after buying an additional 14,481 shares during the period. 55.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on APYX. Craig Hallum raised Apyx Medical to a “strong-buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th. Finally, BTIG Research started coverage on shares of Apyx Medical in a research note on Thursday, October 17th. They issued a “neutral” rating for the company.

Apyx Medical Trading Down 0.6 %

Shares of APYX traded down $0.01 during trading hours on Friday, hitting $1.68. The company had a trading volume of 33,846 shares, compared to its average volume of 80,729. Apyx Medical has a 52-week low of $0.97 and a 52-week high of $2.80. The company has a quick ratio of 4.52, a current ratio of 5.46 and a debt-to-equity ratio of 3.03. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.34. The firm has a market cap of $63.24 million, a P/E ratio of -2.02 and a beta of 1.27.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue of $11.49 million for the quarter, compared to analysts’ expectations of $11.66 million. Apyx Medical had a negative return on equity of 137.98% and a negative net margin of 58.59%. During the same period in the previous year, the firm earned ($0.13) EPS. On average, research analysts predict that Apyx Medical will post -0.68 EPS for the current year.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.